InMed Pharmaceuticals (INM) Income from Continuing Operations (2021 - 2026)

InMed Pharmaceuticals has reported Income from Continuing Operations for 6 years, with the latest figure at -$2.8 million in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 35.06% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$7.9 million, a 4.81% increase from a year earlier, with the FY2025 full-year figure at -$8.2 million, down 6.34% from the prior year.
• Income from Continuing Operations was -$2.8 million for Q1 2026 at InMed Pharmaceuticals, down from -$2.0 million in the prior quarter.
• The five-year high for Income from Continuing Operations was -$336591.0 in Q2 2023, with the low at -$7.9 million in Q2 2022.
• Average Income from Continuing Operations over 5 years is -$2.4 million, with a median of -$2.0 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 95.72% in 2023, then slumped 473.57% in 2024.
• Over 5 years, Income from Continuing Operations stood at -$2.1 million in 2022, then grew by 29.55% to -$1.5 million in 2023, then slumped by 74.2% to -$2.6 million in 2024, then grew by 21.23% to -$2.0 million in 2025, then plunged by 37.65% to -$2.8 million in 2026.
• The last three Income from Continuing Operations figures came in at -$2.8 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.